Abstract
Novel adenosine diphosphate (ADP) P2Y12 antagonists such as prasugrel, ticagrelor, cangrelor, and elinogrel are in various phases of clinical development. These ADP P2Y12 antagonists have advantages over clopidogrel ranging from faster onset to greater and less variable inhibition of platelet function. Novel ADP P2Y12 antagonists are under investigation to determine whether their use can result in improved antiplatelet activity, faster onset of action, and/or greater antithrombotic effects than clopidogrel without an unacceptable increase in hemorrhagic or other side effects. Prasugrel (CS-747; LY-640315), a novel third-generation oral thienopyridine, is a specific, irreversible antagonist of the platelet ADP P2Y12 receptor. Pre-clinical and early phase clinical studies have shown prasugrel to be characterized by more potent antiplatelet effects, lower inter-individual variability in platelet response, and faster onset of activity compared to clopidogrel. Recent findings from large-scale phase-III testing show prasugrel to be more efficacious in preventing ischemic events in acute coronary syndrome patients undergoing percutaneous coronary intervention (PCI); however, this is achieved at the expense of an increased risk of bleeding. Prasugrel provides more rapid and consistent platelet inhibition than clopidogrel.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cannon, C.P., Husted, S., Harrington, R.A., et al. (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol 50, 1844–51.
Greenbaum, A.B., Grines, C.L., Bittl, J.A., et al. (2006) Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial Am Heart J 151, 689.
Becker, R.C., Moliterno, D.J., Jennings, L.K., Pieper, K.S., Pei, J., Niederman, A., Ziada, K.M., Berman, G., Strony, J., Joseph, D., Mahaffey, K.W., Van de Werf, F., Veltri, E., and Harrington, R.A, and for the TRA-PCI Investigators. (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study Lancet 373, 919–28.
Nguyen, T.A., Diodati, J.G. and Pharand, C. (2005) Resistance to clopidogrel: a review of the evidence JACC 45, 1157–64.
Jakubowski, J.A., Payne, C.D., Li, Y.G., et al. (2008) A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry Thromb Haemost 99, 215–22.
Farid, N., McIntosh, M., Garofolo, F., et al. (2007) Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry Rapid Commun Mass Spectrom 21, 169–79.
Brandt, J.T., Payne, C.D., Wiviott, S.D., et al. (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153, e9–16.
Jakubowski, J.A., Matsushima, N., Asai, F., et al. (2007) A multiple dose study of prasugrel (CS- 747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans Br J Clin Pharmacol 63, 421–30.
Haynes, R.B., Sandler, R.S., Larson, E.B., et al. (1992) A critical appraisal of ticlopidine, a new antiplatelet agent: effectiveness and clinical indications for prophylaxis of atherosclerotic events Arch Intern Med 152, 1376–80.
Jernberg, T., Payne, C.D., Winters, K.J., et al. (2006) Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27, 1166–73.
Wiviott, S.D., Antman, E.M., Winters, K.J., et al. (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial Circulation 111, 3366–73.
Wiviott, S.D., Trenk, D., Frelinger, A.L., et al. (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation – thrombolysis in myocardial infarction 44 trial Circulation 116, 2923–32.
Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357, 2001–15.
Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITONTIMI 38 trial: a sub-analysis of a randomized trial Lancet 371, 1353–63.
Antman, E.M., Wiviott, S.D., Murphy, S.A., et al. (2008) Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel – Thrombolysis in Myocardial Infarction) J Am Coll Cardiol 51, 2028–33.
Floyd, J., and Wolfe, S. (2009) Prasugrel STEMI subgroup analysis Lancet 373, 1845–6.
Webster, M.W., and Gladding, P. (2009) Prasugrel STEMI subgroup analysis Lancet 373, 1846–8.
Spinler, S.A., and Rees, C. (2009) Review of prasugrel for the secondary prevention of atherothrombosis J Manag Care Pharm 15, 383–95.
Small, D.S., Wrishko, R.E., Ernest, C.S. 2nd, Ni, L., Winters, K.J., Farid, N.A., Li, Y.G., Brandt, J.T., Salazar, D.E., Borel, A.G., Kles, K.A., and Payne, C.D. (2009) Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease J Clin Pharm Ther 34, 585–94.
Small, D.S., Farid, N.A., Li, Y.G., Ernest, C.S. 2nd, Winters, K.J., Salazar, D.E., and Payne, C.D. (2009) Pharmacokinetics and pharmacodynamic of prasugrel in subjects with moderate liver disease J Clin Pharm Ther 34, 575–83.
Montalescot, G., Wiviott, S.D., Braunwald, E., Murphy, S.A., Gibson, C.M., McCabe, C.H., Antman, E.M., for the TRITON-TIMI 38 Investigators. (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial Lancet 373, 723–31.
Anderluh, M., and Dolenc, M.S. (2002) Thrombin receptor antagonists; recent advances in PAR-1 antagonist development Curr Med Chem 9, 1229–50.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Mousa, S.A., Jeske, W.P., Fareed, J. (2010). Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist. In: Mousa, S. (eds) Anticoagulants, Antiplatelets, and Thrombolytics. Methods in Molecular Biology, vol 663. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-803-4_8
Download citation
DOI: https://doi.org/10.1007/978-1-60761-803-4_8
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-802-7
Online ISBN: 978-1-60761-803-4
eBook Packages: Springer Protocols